Loading...

Halozyme Therapeutics, Inc.

HALONASDAQ
Healthcare
Biotechnology
$52.02
$0.00(0.00%)

Halozyme Therapeutics, Inc. (HALO) Stock Overview

Explore Halozyme Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

A

Score: 82.0/100

Key Financials

Market Cap6.5B
P/E Ratio13.46
EPS (TTM)$3.76
ROE1.22%
Fundamental Analysis

AI Price Forecasts

1 Week$49.48
1 Month$58.89
3 Months$67.98
1 Year Target$64.32

HALO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Halozyme Therapeutics, Inc. (HALO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $64.32.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 13.46 and a market capitalization of 6.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
22.44%
22.44%
Profit Growth
$3.94
57.71%
EPS Growth
$3.94
64.32%
Operating Margin
55.10%
63.36%
ROE
122.24%
57.71%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
3
Hold
3
Sell
0
Strong Sell
0

Price Targets

Low$52.00
Average$57.00
High$62.00

Company Profile

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

CEO

Helen I. Torley M.B. Ch. B., M.R.C.P.

Employees

350

Headquarters

11388 Sorrento Valley Road, San Diego, CA

Founded

2004

Frequently Asked Questions

;